These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 2153905)
1. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905 [TBL] [Abstract][Full Text] [Related]
2. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302 [TBL] [Abstract][Full Text] [Related]
3. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Deffie AM; Batra JK; Goldenberg GJ Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693 [TBL] [Abstract][Full Text] [Related]
4. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765 [TBL] [Abstract][Full Text] [Related]
5. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973 [TBL] [Abstract][Full Text] [Related]
6. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Wolverton JS; Danks MK; Schmidt CA; Beck WT Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902 [TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227 [TBL] [Abstract][Full Text] [Related]
9. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377 [TBL] [Abstract][Full Text] [Related]
10. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Poddevin B; Riou JF; Lavelle F; Pommier Y Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227 [TBL] [Abstract][Full Text] [Related]
11. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line. Patel S; Austin CA; Fisher LM Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515 [TBL] [Abstract][Full Text] [Related]
12. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930 [TBL] [Abstract][Full Text] [Related]
13. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226 [TBL] [Abstract][Full Text] [Related]
15. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045 [TBL] [Abstract][Full Text] [Related]
16. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Friche E; Danks MK; Schmidt CA; Beck WT Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312 [TBL] [Abstract][Full Text] [Related]
17. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057 [TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
19. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009 [TBL] [Abstract][Full Text] [Related]
20. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Deffie AM; Bosman DJ; Goldenberg GJ Cancer Res; 1989 Dec; 49(24 Pt 1):6879-82. PubMed ID: 2555055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]